Method of treating cancer using selective estrogen receptor modulators
US-2016324808-A1 · Nov 10, 2016 · US
Substituted androst-4-ene diones
US8969327B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-8969327-B2 |
| Application number | US-201113635924-A |
| Country | US |
| Kind code | B2 |
| Filing date | Apr 7, 2011 |
| Priority date | Apr 8, 2010 |
| Publication date | Mar 3, 2015 |
| Grant date | Mar 3, 2015 |
How to read this patent
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
- Title
What the patent document calls the invention.
- Abstract
A short plain-language summary of the technical disclosure.
- Assignees and inventors
Who owns or filed the patent and who is credited as inventor.
- Key dates
Filing, priority, publication, and grant dates set the timeline.
- First independent claim
The legal scope of protection — read this for what is actually claimed.
- CPC / IPC classifications
Technology tags used to group this patent with similar filings.
- Citations and related patents
Prior art links and similar publications in this corpus.
Abstract
Official abstract text for this publication.
The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and its intermediates. These compounds can also be used in the treatment of other hormone-related disorders, including benign prostatic hyperplasia, cardiovascular disease, and neurodegenerative disorders.
First claim
Opening claim text (preview).
The invention claimed is: 1. A compound of Formula C, which is or a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable ester thereof, wherein R 2 is selected from the group consisting of an alkenyl group and an alkynyl group, either of which may be optionally substituted. 2. A compound of claim 1 , wherein the substit…
Assignees
Inventors
Classifications
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Chemistry & Metallurgy · mapped topic
Human Necessities · mapped topic
Chemistry & Metallurgy · mapped topic
Patent family
Related publications grouped by family.
External sources
Next steps
Free tools are coming soon. Tell us what you want to track and we'll notify you.
Frequently asked questions
Answers are generated from the same data shown on this page.
- What does patent US8969327B2 cover?
- The disclosure relates to novel C4 and C6 substituted androst-4-ene diones as well as andros-1,4-diene diones and derivatives thereof, their process of preparation, pharmaceutical compounds containing them, and the use of said compounds for the treatment of hormone-related disorders in mammals. This includes hormone-dependent cancers, particularly those caused by elevated levels of estrogen and…
- Who is the assignee on this patent?
- Davies Huw, Ghosh Dabashis, Morton Daniel, and 3 more
- What technology area does this patent fall under?
- Primary CPC classification A61K31/5685. Mapped technology areas include Human Necessities.
- When was this patent published?
- Publication date Tue Mar 03 2015 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
- What related patents are in patentsdb?
- We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).